Zymeworks ZWI-ZW25-201
Trial Overview
Official Title
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), And Colorectal Cancer (CRC)
Study Purpose
To determine if the experimental study drug ZW25 is safe and effective in the treatment of HER2-expressing GI cancers
Diagnosis
Patient who have been diagnosed with one of the following human epidermal growth factor receptor 2 (HER2)-expressing gastrointestinal cancers • Gastroesophageal adenocarcinoma • Biliary tract cancer • Colorectal cancerEligibility
Patients with unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA, BTC, or CRC
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Intervention
First-line, study to investigate the safety, tolerability, and antitumor activity of ZW25 plus standard 1st line combination chemotherapy regimens of physician choice
For more information, visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
ZWI-ZW25-201